Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016–2020: a retrospective observational study based on inpatient and outpatient hospital data
Objectives It is unclear whether the use of antineoplastic drugs for patients with lung cancer in China has changed after the implementation of the national drug price negotiation in 2016 and continual update of clinical guidelines. This study aims to evaluate the trends in antineoplastic drug use,...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-03-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/13/3/e069645.full |
| _version_ | 1797744272886202368 |
|---|---|
| author | Yi Liu Lixin Zhou Xiaohong Zhang Feng Yang Rongrong Fan Jingyuan Shang Lin Huang Yanguo Liu Chunyan Zhang Li'an Zu Yufei Feng |
| author_facet | Yi Liu Lixin Zhou Xiaohong Zhang Feng Yang Rongrong Fan Jingyuan Shang Lin Huang Yanguo Liu Chunyan Zhang Li'an Zu Yufei Feng |
| author_sort | Yi Liu |
| collection | DOAJ |
| description | Objectives It is unclear whether the use of antineoplastic drugs for patients with lung cancer in China has changed after the implementation of the national drug price negotiation in 2016 and continual update of clinical guidelines. This study aims to evaluate the trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in major cities of China.Design We conducted a retrospective observational study using data from January 2016 to December 2020.Setting This study used prescription records based on inpatient and outpatient hospital data from 97 hospitals in 9 major cities of China.Participants A total of 218 325 antineoplastic drug prescriptions in patients with lung cancer were retrospectively collected from the Hospital Prescription Analysis Cooperative Project during the study period.Outcome measures Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer.Results The yearly antineoplastic prescriptions increased by 85.6% from 28 594 in 2016 to 53 063 in 2020 (Z=1.71, p=0.086). Significant increases were seen in the prescriptions for protein kinase inhibitors (PKIs) and monoclonal antibodies (mAbs), whereas significant decreases were observed in antimetabolites, plant alkaloids and platinum compounds. The yearly cost increased progressively by 145.0% from ¥113.6 million in 2016 to ¥278.3 million in 2020 (Z=2.20, p=0.027). The top three anticancer drug classes in terms of total cost were PKIs, antimetabolites and mAbs. In prescribing patterns of antineoplastic agents for lung cancer, monotherapy, and triple or more drug combinations gradually increased, while dual combinations decreased significantly from 30.8% to 19.6%.Conclusions Prescription practices among patients with lung cancer in China underwent major changes during the study period. The observed trends can aid in understanding the present medication use status of patients with lung cancer in China and provide information for future drug management. |
| first_indexed | 2024-03-12T15:07:22Z |
| format | Article |
| id | doaj.art-7b2f8413a92141228fb2aae136c07c3a |
| institution | Directory Open Access Journal |
| issn | 2044-6055 |
| language | English |
| last_indexed | 2024-03-12T15:07:22Z |
| publishDate | 2023-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj.art-7b2f8413a92141228fb2aae136c07c3a2023-08-12T07:10:07ZengBMJ Publishing GroupBMJ Open2044-60552023-03-0113310.1136/bmjopen-2022-069645Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016–2020: a retrospective observational study based on inpatient and outpatient hospital dataYi Liu0Lixin Zhou1Xiaohong Zhang2Feng Yang3Rongrong Fan4Jingyuan Shang5Lin Huang6Yanguo Liu7Chunyan Zhang8Li'an Zu9Yufei Feng101 Department of Infectious Diseases, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi`an, Shaanxi, ChinaDepartment of Thoracic Surgery, Peking University People’s Hospital, Beijing, ChinaDepartment of Pharmacy, Peking University People’s Hospital, Beijing, ChinaDepartment of Thoracic Surgery, Peking University People’s Hospital, Beijing, ChinaDepartment of Thoracic Surgery, Peking University People’s Hospital, Beijing, ChinaDepartment of Pharmacy, Peking University People’s Hospital, Beijing, ChinaDepartment of Pharmacy, Peking University People’s Hospital, Beijing, ChinaDepartment of Thoracic Surgery, Peking University People’s Hospital, Beijing, ChinaDepartment of Pharmacy, Peking University People’s Hospital, Beijing, ChinaDepartment of Thoracic Surgery, Peking University People’s Hospital, Beijing, ChinaDepartment of Pharmacy, Peking University People’s Hospital, Beijing, ChinaObjectives It is unclear whether the use of antineoplastic drugs for patients with lung cancer in China has changed after the implementation of the national drug price negotiation in 2016 and continual update of clinical guidelines. This study aims to evaluate the trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in major cities of China.Design We conducted a retrospective observational study using data from January 2016 to December 2020.Setting This study used prescription records based on inpatient and outpatient hospital data from 97 hospitals in 9 major cities of China.Participants A total of 218 325 antineoplastic drug prescriptions in patients with lung cancer were retrospectively collected from the Hospital Prescription Analysis Cooperative Project during the study period.Outcome measures Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer.Results The yearly antineoplastic prescriptions increased by 85.6% from 28 594 in 2016 to 53 063 in 2020 (Z=1.71, p=0.086). Significant increases were seen in the prescriptions for protein kinase inhibitors (PKIs) and monoclonal antibodies (mAbs), whereas significant decreases were observed in antimetabolites, plant alkaloids and platinum compounds. The yearly cost increased progressively by 145.0% from ¥113.6 million in 2016 to ¥278.3 million in 2020 (Z=2.20, p=0.027). The top three anticancer drug classes in terms of total cost were PKIs, antimetabolites and mAbs. In prescribing patterns of antineoplastic agents for lung cancer, monotherapy, and triple or more drug combinations gradually increased, while dual combinations decreased significantly from 30.8% to 19.6%.Conclusions Prescription practices among patients with lung cancer in China underwent major changes during the study period. The observed trends can aid in understanding the present medication use status of patients with lung cancer in China and provide information for future drug management.https://bmjopen.bmj.com/content/13/3/e069645.full |
| spellingShingle | Yi Liu Lixin Zhou Xiaohong Zhang Feng Yang Rongrong Fan Jingyuan Shang Lin Huang Yanguo Liu Chunyan Zhang Li'an Zu Yufei Feng Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016–2020: a retrospective observational study based on inpatient and outpatient hospital data BMJ Open |
| title | Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016–2020: a retrospective observational study based on inpatient and outpatient hospital data |
| title_full | Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016–2020: a retrospective observational study based on inpatient and outpatient hospital data |
| title_fullStr | Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016–2020: a retrospective observational study based on inpatient and outpatient hospital data |
| title_full_unstemmed | Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016–2020: a retrospective observational study based on inpatient and outpatient hospital data |
| title_short | Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016–2020: a retrospective observational study based on inpatient and outpatient hospital data |
| title_sort | trends in antineoplastic drug use cost and prescribing patterns among patients with lung cancer in nine major cities of china 2016 2020 a retrospective observational study based on inpatient and outpatient hospital data |
| url | https://bmjopen.bmj.com/content/13/3/e069645.full |
| work_keys_str_mv | AT yiliu trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT lixinzhou trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT xiaohongzhang trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT fengyang trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT rongrongfan trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT jingyuanshang trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT linhuang trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT yanguoliu trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT chunyanzhang trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT lianzu trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata AT yufeifeng trendsinantineoplasticdrugusecostandprescribingpatternsamongpatientswithlungcancerinninemajorcitiesofchina20162020aretrospectiveobservationalstudybasedoninpatientandoutpatienthospitaldata |